Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. - Wikidata - wikimedia - TriplyDB

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

http://www.wikidata.org/entity/Q41233814

about

Bioresorbable vascular scaffolds technology: current use and future developments MicroRNAs and Endothelial (Dys) Function A Review of the Key Clinical Trials of 2015: Results and Implications Endothelial repair in stented arteries is accelerated by inhibition of Rho-associated protein kinase New-Generation Coronary Stents: Current Data and Future Directions.Procedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: a single-centre experience.Current Status and Future Perspective of Stenting for Symptomatic Intracranial Atherosclerotic Disease: A Meta-Analysis.Clinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A Systematic Literature Review.Role of invasive imaging in acute and long-term assessment of bioresorbable scaffold technology."The scaffolding must be removed once the house is built"-spontaneous coronary artery dissection and the potential of bioresorbable scaffolds.Two-year Optical Coherence Tomography Findings after Balloon-Only Treatment of Bioresorbable Scaffold Restenosis in a Calcified Coronary Lesion: A Case Report.Patient profile and periprocedural outcomes of bioresorbable vascular scaffold implantation in comparison with drug-eluting and bare-metal stent implantation. Experience from ORPKI Polish National Registry 2014-2015.Development of a New Hybrid Biodegradable Drug-Eluting Stent for the Treatment of Peripheral Artery Disease Clinical outcomes of overlapping versus non-overlapping everolimus-eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov identifier: NCT02298413).Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB III, ABSORB China, and ABSORB Japan.Everolimus-eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, single-center initial experience.Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study.Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge.The year in cardiology 2015: coronary intervention.Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions : 2017 revision.Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding Controversies surrounding percutaneous coronary intervention in the diabetic patient.Percutaneous Coronary Intervention: 2015 in Review.Bioresorbable drug-eluting scaffolds for treatment of vascular disease.Comparison of a Drug-Free Early Programmed Dismantling PDLLA Bioresorbable Scaffold and a Metallic Stent in a Porcine Coronary Artery Model at 3-Year Follow-Up.Late breaking trials of 2015 in coronary artery disease: Commentary covering ACC, EuroPCR, SCAI, TCT, ESC, and AHA.Enhanced biocompatibility of CD47-functionalized vascular stents.The unmet needs: How future technologies will address current limitations of bioresorbable scaffold technology.Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients.Surrogate and clinical endpoints in interventional cardiology: are statistics the brakes?Bioresorbable scaffolds: the fee comes now and the reward comes later.Optimisation of percutaneous coronary intervention: indispensables for bioresorbable scaffolds.Bioresorbable Scaffolds for Coronary Stenosis: When and How Based Upon Current Studies.Bioresorbable Polymers and Stent Devices.Bioresorbable vascular scaffolds - basic concepts and clinical outcome.Single or dual antiplatelet therapy after PCI.Stents: Biomechanics, Biomaterials, and Insights from Computational Modeling.Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.A review of bioresorbable scaffolds: hype or hope?Long-Term Follow-Up of Patients after Percutaneous Coronary Intervention with Everolimus-Eluting Bioresorbable Vascular Scaffold.

P2860

Q26741147-8E4F14C6-F531-4D3A-9CC1-6FB291004595 Q26775547-32829312-25C7-4A03-8F1B-D4605F6B795F Q28077170-C3CCE83D-17E5-4396-A7F5-8D9927A49E2C Q30832055-C3B4C45D-CCDC-46E7-BEA8-D20B69140CA8 Q31164040-156DF5A3-332D-402F-AD13-BDC5F8BBD3DB Q33612614-5F48A3B4-5635-4B88-AD46-75DD378B7CAA Q33862275-73D3AACC-93B1-487D-858F-5C51A8F1F081 Q35884429-0649F258-6E1C-43C2-9D30-09D686E0C42D Q36178330-24C48E47-E0B8-433F-AF4E-C8ECCE8CE882 Q37411195-A1AF52B0-C4AD-421B-8C19-354E1F2C89F9 Q37444702-2E5D8ED1-99EB-4EF4-B259-B1BF4DFA2DB7 Q37463810-8C23D924-F1BF-4152-818E-BB7E898DEB0B Q37483241-9CEDCD92-131D-41AA-A736-AA18FECC9E3D Q38376848-CD0DBDF3-47C0-4724-8C46-7FBFFFB022AF Q38472279-57E35146-163D-4E3B-94B0-6CFD5AB3C8DB Q38629269-CD494A75-4A9C-42A4-9265-E158D65EBB45 Q38657816-D0D810C4-08F3-4931-BCF3-273A21E8CAF0 Q38676248-44BF6A26-75BC-41B2-8232-5F91175D3613 Q38685684-0DA74276-FBB6-40A1-BAEC-A39432D77063 Q38712687-D84B4A7E-3999-43CD-9BC2-71DA5321AA6D Q38714351-155BE2F6-C808-427E-8CAA-0BF62899B7B8 Q38720113-AD1AD048-0A1E-473A-8B3F-29C64F0F4F05 Q38728869-97C50364-4732-43C6-8E5C-E7F90ECF701D Q38728978-3B895CFF-E160-46A5-BE80-213611502A51 Q38733043-A6C80765-6135-4263-8CF8-5385F7971B3E Q38762240-3D87FA89-33EA-4F35-97F4-C3EF4B338DB7 Q38791109-3FE1314E-5DF1-4BD0-8034-C6D5199AFB89 Q38802127-82B9F988-6B7C-492B-9FD8-1FE849932264 Q38824733-452919F7-B7CB-4B4A-B4B4-7BEF1D5EAACC Q38845289-506100B2-BE9A-47B0-B6DF-EDBB02E8CE22 Q38854464-B018D586-8856-418F-B045-525485170AE4 Q38885397-D8DB3380-7C2E-4140-A434-F7C604851DEC Q38904242-23D124A3-DE5A-474B-9093-E162C7C16505 Q38919254-C6A8E836-7C06-43B6-A2F9-CA1E9570673E Q38967027-6EDBD449-191D-41E2-A6DB-5ECA4D742C83 Q38970275-32D990E4-E746-49EF-9D64-8676BCCBD6CA Q38979758-533D560C-3BFC-4B57-BB92-C42F2F3C1E3B Q38995006-CC4E39B7-CD8F-4398-87FF-BFDB0867E382 Q39014983-C53EAB89-F128-4C49-BBB5-757E31CADA45 Q39027044-746A3635-2895-49E7-8930-AC5ACFC16119

P2860

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

http://www.wikidata.org/entity/Q41233814

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

@en

type

label

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

@en

prefLabel

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

@en

P1433

Q41233814-8ED25ED2-B9DB-49BD-ABBE-8E0F518519F7

P1476

Q41233814-FEF2881A-8B03-4453-8D71-21FCF1D7375E

P2093

Q41233814-2DB94D3F-3064-4F81-BE10-AB3492B7FE71

Q41233814-4641D500-F633-41F4-A42C-7FB77A95A448

Q41233814-58F6E8F7-A820-43D3-8934-C431C81014DA

Q41233814-5FA4C971-532F-4562-9C57-8C5C8D9FBCC9

Q41233814-659E090A-7F77-4380-91EB-E7754E70C7D8

Q41233814-77F4369C-FCB2-4EDB-B763-90C463979104

Q41233814-A7D45945-1CED-4800-9B22-4B80A223ABAC

Q41233814-A8917BAA-4A62-4B0E-86B4-99134E098C14

Q41233814-AE16DE8A-D523-49E5-A138-CE8AC384E0B3

Q41233814-BB1B4312-5758-41F4-A749-90CB41FC6EB8

P304

Q41233814-EA62CBF3-F142-422B-BE79-895DEBA33CE5

P31

Q41233814-544A8A9B-9141-4339-B0FB-125751D388AE

P356

Q41233814-6A00437A-ECA1-4197-B773-AB62AFCD9D74

P407

Q41233814-31FF9889-6805-4A9F-ACFA-A3B1575A9FA1

P433

Q41233814-23D4117D-35FE-445F-8DDC-8900A330174E

P478

Q41233814-FE170DE0-C432-4287-8ED0-5ED13F13A6A9

P50

Q41233814-5F10D1B5-0CEF-4CBB-BBA4-4C65B6E41C6B

Q41233814-D0A4A386-E4C8-453F-9EF5-4C4C21CA25CF

P577

Q41233814-01DEF7B1-50F6-4BAB-9C71-19CB54C8627B

P698

Q41233814-EA82496B-2EF9-4D91-BBDF-BA04D7A36E02

P356

P1433

The New England Journal of Medicine

P1476

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

@en

P2093

ABSORB III Investigators

http://www.w3.org/2001/XMLSchema#string

Ameer Kabour

http://www.w3.org/2001/XMLSchema#string

Annapoorna Kini

http://www.w3.org/2001/XMLSchema#string

Charles Simonton

http://www.w3.org/2001/XMLSchema#string

D Christopher Metzger

http://www.w3.org/2001/XMLSchema#string

David G Rizik

http://www.w3.org/2001/XMLSchema#string

Dean J Kereiakes

http://www.w3.org/2001/XMLSchema#string

Gregg W Stone

http://www.w3.org/2001/XMLSchema#string

Marc R Litt

http://www.w3.org/2001/XMLSchema#string

Paul S Teirstein

http://www.w3.org/2001/XMLSchema#string

P304

1905-1915

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1509038

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Stephen G. Ellis

Jeffrey J Popma

P577

2015-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26457558

http://www.w3.org/2001/XMLSchema#string